Acquisition Announced

Boston Scientific acquisition of Penumbra

US$15bn enterprise value

Announced 15 Jan 2026 · NYSE: PEN · US$374.00 cash and scrip per share

Advisers

Penumbra

Target

Financial adviser
Legal adviser
Fairness opinion

Boston Scientific

Acquirer

Legal adviser
A&O Shearman (as Allen Overy Shearman & Sterling LLP)
Target
Penumbra
Acquirer
Boston Scientific
Target based in
United States
Buyer based in
United States
Equity value
US$15bn
Sector
Medtech

In the league tables

Similar deals

All medtech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.